OR WAIT null SECS
November 18, 2026
Article
Pooled, blinded week 12 data from the phase 2 RENEW trial showed FVC improvement in 8 of 24 patients with IPF and no treatment-related serious AEs.
October 31, 2026
Video
Rohit Gupta, MD, discusses advanced pulmonary sarcoidosis, antifibrotic uncertainty, and first-line methotrexate data after a CHEST 2026 session.
October 27, 2026
Colin Church, MBBS, PhD, discusses durable 6MWD and NT-proBNP signals in a TPIP open-label extension and what phase 3 needs to show next.
Colin Church, MBBS, PhD, discusses 24-month open-label extension data showing TPIP remains tolerable in patients with PH-ILD, with no new safety signals.
October 20, 2026
In 503 patients with ILD, telomere length below the 10th percentile was linked to UIP pattern on CT and higher MIL-UIP scores but not greater fibrosis extent.
October 19, 2026
Plasma and exhaled breath sphingolipid signatures differed between IPF and fibrotic hypersensitivity pneumonitis.
October 12, 2026
Topline phase 3 ALOFT-IPF data show admilparant 60 mg improved 52-week FVC vs placebo in IPF, while the 120 mg dose missed statistical significance.
September 16, 2026
George, of Royal Brompton Hospital discusses a phase 2a post hoc analysis showing increases in lung volume and reduced ILD.
September 15, 2026
Wuyts, of University Hospitals Leuven discusses interim FIBRONEER-ON open-label extension data showing nerandomilast's favorable safety profile.
Marlies Wijsenbeek, MD, PhD, of Erasmus MC discusses BI 1839100, a TRPA1 antagonist, which missed its week-4 endpoint in a phase 2/2b trial.